Dr. Reddy’s Share Price Rises 3% As Firm Dismisses Report On Job Cuts
Shares of Dr Reddy's Laboratories rose over 3% in early trade on Tuesday after the company denied reports claiming it was undertaking a 25% reduction in workforce costs through large-scale layoffs.
In an exchange filing, the company said it “categorically denies” the claims made in a Business Standard report which suggested that senior executives, including those earning over Rs 1 crore per annum, had been asked to resign. The report also alleged that employees aged 50-55 in the research and development division were offered voluntary retirement.
Calling the report “factually incorrect,” Dr Reddy's said, “The company does not comment on market speculations, and there is currently no such event or information which requires a disclosure.”
The news report linked the alleged cost-cutting to margin pressures from Dr Reddy's generic version of Revlimid and underperformance in newer ventures such as nutraceuticals and digital therapeutics.
The company has been on an expansion path, ramping up hiring in recent years ahead of its joint venture with Nestlé and fresh product launches.
Dr. Reddy's Share Price Today
Dr. Reddy's stock rose as much as 3.45% during the day to Rs 1,147.80 apiece on the NSE. It was trading 2.92% higher at Rs 1141.90 apiece, compared to a 2% advance in the benchmark Nifty 50 as of 9:26 a.m.
It has fallen 4.80% in the last 12 months and 17.57% on a year-to-date basis. The relative strength index was at 50.20.
Fifteen out of the 40 analysts tracking the pharma company have a 'buy' rating on the stock, 11 recommend a 'hold' and 14 suggest a 'sell', according to Bloomberg data. The 12-month analysts' consensus target price on the stock is Rs 1338.36, implying an upside of 20.6%.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
